[Skip to Content]
[Skip to Content Landing]
Views 722
Citations 0
Editorial
October 30, 2017

Macrolides and Pediatric Community-Acquired Pneumonia—Time for a Paradigm Shift?

Author Affiliations
  • 1Division of Pediatric Infectious Diseases, Duke University, Durham, North Carolina
JAMA Pediatr. Published online October 30, 2017. doi:10.1001/jamapediatrics.2017.3828

Azithromycin is one of the most commonly used antibiotics in pediatrics. It was prescribed to 12.2 million outpatients in 2013, accounting for almost 20% of all antibiotic prescriptions for children in the ambulatory setting.1 Much of this use is inappropriate either because a more narrow-spectrum agent would suffice or because antibiotics are not needed at all. One of the few pediatric indications for macrolides is community-acquired pneumonia (CAP); nearly one-third of hospitalized children admitted to freestanding children’s hospitals with CAP are treated with a macrolide.2 Although this is standard of care, the study by Williams and colleagues3 in this issue of JAMA Pediatrics questions the necessity of this practice.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×